• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's After-Market Session

    11/28/22 4:32:39 PM ET
    $ADVM
    $AGTC
    $CLNN
    $KALA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ADVM alert in real time by email

    Gainers

    • Kala Pharmaceuticals (NASDAQ:KALA) stock rose 24.8% to $7.09 during Monday's after-market session. This security traded at a volume of 108.5K shares come close, making up 65.4% of its average volume over the last 100 days. The market value of their outstanding shares is at $10.7 million.
    • Clene (NASDAQ:CLNN) shares moved upwards by 9.25% to $1.18. The company's market cap stands at $87.1 million.
    • NanoVibronix (NASDAQ:NAOV) shares rose 8.94% to $0.69. NanoVibronix's trading volume hit 1.2 million shares by close, accounting for 357.8% of its average volume over the last 100 days. The market value of their outstanding shares is at $19.3 million.
    • Schrodinger (NASDAQ:SDGR) stock moved upwards by 5.03% to $18.37. The company's market cap stands at $1.3 billion.
    • Adverum Biotechnologies (NASDAQ:ADVM) shares moved upwards by 4.99% to $0.71. The company's market cap stands at $71.2 million.
    • OpGen (NASDAQ:OPGN) stock increased by 4.99% to $0.18. The market value of their outstanding shares is at $9.6 million.

    Losers

    • Alaunos Therapeutics (NASDAQ:TCRT) shares decreased by 20.9% to $0.69 during Monday's after-market session. Alaunos Therapeutics's trading volume hit 182.7K shares by close, accounting for 4.9% of its average volume over the last 100 days. The market value of their outstanding shares is at $149.1 million.
    • Pyxis Oncology (NASDAQ:PYXS) stock declined by 10.35% to $1.3. The company's market cap stands at $45.6 million.
    • Tricida (NASDAQ:TCDA) shares decreased by 5.2% to $0.27. Today's trading volume for this security ended up closing at 2.8 million shares, which is 33.7 percent of its average volume over the last 100 days. The company's market cap stands at $15.6 million.
    • Rubius Therapeutics (NASDAQ:RUBY) shares declined by 4.77% to $0.2. The company's market cap stands at $18.2 million.
    • Applied Genetic Techs (NASDAQ:AGTC) stock fell 4.01% to $0.36. Today's trading volume for this security ended up closing at 52.0K shares, which is 4.3 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $24.3 million.
    • Otonomy (NASDAQ:OTIC) shares declined by 3.37% to $0.1. This security traded at a volume of 171.0K shares come close, making up 5.9% of its average volume over the last 100 days. The market value of their outstanding shares is at $5.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADVM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADVM
    $AGTC
    $CLNN
    $KALA

    CompanyDatePrice TargetRatingAnalyst
    Schrodinger Inc.
    $SDGR
    12/15/2025$24.00Neutral → Buy
    BofA Securities
    Adverum Biotechnologies Inc.
    $ADVM
    11/17/2025Buy → Neutral
    H.C. Wainwright
    Pyxis Oncology Inc.
    $PYXS
    11/3/2025$9.00Buy
    Stifel
    KALA BIO Inc.
    $KALA
    9/30/2025$1.50Outperform → Neutral
    Mizuho
    Schrodinger Inc.
    $SDGR
    9/30/2025$19.00Neutral
    Goldman
    KALA BIO Inc.
    $KALA
    9/29/2025Buy → Neutral
    H.C. Wainwright
    KALA BIO Inc.
    $KALA
    9/29/2025Buy → Neutral
    Ladenburg Thalmann
    KALA BIO Inc.
    $KALA
    9/8/2025$30.00Outperform
    Mizuho
    More analyst ratings

    $ADVM
    $AGTC
    $CLNN
    $KALA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Abrams Therese Marie

    3 - Schrodinger, Inc. (0001490978) (Issuer)

    3/19/26 8:04:11 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CAO Herman Jenny sold $17,764 worth of shares (1,383 units at $12.84), decreasing direct ownership by 4% to 34,804 units (SEC Form 4)

    4 - Schrodinger, Inc. (0001490978) (Issuer)

    3/6/26 5:29:46 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & CFO Jain Rachit sold $21,033 worth of shares (1,631 units at $12.90), decreasing direct ownership by 3% to 52,596 units (SEC Form 4)

    4 - Schrodinger, Inc. (0001490978) (Issuer)

    3/6/26 5:29:05 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADVM
    $AGTC
    $CLNN
    $KALA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Schrodinger upgraded by BofA Securities with a new price target

    BofA Securities upgraded Schrodinger from Neutral to Buy and set a new price target of $24.00

    12/15/25 9:09:21 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adverum Biotech downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Adverum Biotech from Buy to Neutral

    11/17/25 9:39:07 AM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Stifel resumed coverage on Pyxis Oncology with a new price target

    Stifel resumed coverage of Pyxis Oncology with a rating of Buy and set a new price target of $9.00

    11/3/25 9:08:29 AM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADVM
    $AGTC
    $CLNN
    $KALA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

    Completed target enrollment in Phase 1 monotherapy dose expansion study of micvotabart pelidotin (MICVO) in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) in the first quarter of 2026 Updated data from MICVO Phase 1 monotherapy study in 2L+ R/M HNSCC on track for mid-year 2026; to include patients treated with modified weight-based dosing and patients treated with total body weight dosing Updated data from MICVO Phase 1/2 dose escalation study in combination with KEYTRUDA® in 1L/2L+ R/M HNSCC on track for the second half of 2026 Announced appointment of Thomas Civik as Interim Chief Executive Officer Expected cash runway into the fourth quarter of 2026 BOSTO

    3/23/26 7:00:00 AM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Red Light Holland Engages Kala Bio's Researgency.AI Platform to Support Clinical Development of Filament's Patented PEX010 Botanical Psilocybin Drug Candidate

    AI-powered autonomous research agents to be deployed in support of PEX010 clinical development strategy, leveraging Kala Bio's purpose-built agentic AI platform for the biotechnology industry TORONTO and ARLINGTON, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- Red Light Holland Corp. (CSE:TRIP) (FSE: 4YX) (OTCQB:TRUFF) ("Red Light" or the "Company") and Kala Bio, Inc. (NASDAQ:KALA) ("Kala Bio") today announced that Red Light has engaged Kala Bio's with its Researgency.ai agentic artificial intelligence platform under world wide license from Younet to support the clinical development strategy for PEX010, the patented botanical psilocybin drug candidate originated by Filament Health Corp. ("Fil

    3/18/26 9:00:00 AM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    Schrödinger, Inc. (NASDAQ:SDGR) today reported that on March 14, 2026, the company granted (i) a non-statutory stock option to purchase 1,950 shares of the company's common stock to one newly hired employee and (ii) restricted stock units (RSUs) with respect to 4,375 shares of the company's common stock to two newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement to such employees' acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(

    3/18/26 8:30:00 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADVM
    $AGTC
    $CLNN
    $KALA
    SEC Filings

    View All

    SEC Form S-8 filed by Pyxis Oncology Inc.

    S-8 - Pyxis Oncology, Inc. (0001782223) (Filer)

    3/23/26 4:05:06 PM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Pyxis Oncology Inc.

    10-K - Pyxis Oncology, Inc. (0001782223) (Filer)

    3/23/26 7:17:26 AM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pyxis Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Pyxis Oncology, Inc. (0001782223) (Filer)

    3/23/26 7:12:28 AM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADVM
    $AGTC
    $CLNN
    $KALA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Matlin David J bought $216,664 worth of shares (33,333 units at $6.50), increasing direct ownership by 7% to 477,824 units (SEC Form 4)

    4 - Clene Inc. (0001822791) (Issuer)

    1/13/26 2:48:54 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO, PRESIDENT AND DIRECTOR Fischer Laurent bought $553,917 worth of shares (128,699 units at $4.30), increasing direct ownership by 177% to 201,513 units (SEC Form 4)

    4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)

    12/8/25 9:45:06 PM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CHIEF OPERATING OFFICER Soparkar Peter bought $211,000 worth of shares (50,000 units at $4.22), increasing direct ownership by 166% to 80,189 units (SEC Form 4)

    4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)

    12/8/25 9:45:04 PM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADVM
    $AGTC
    $CLNN
    $KALA
    Leadership Updates

    Live Leadership Updates

    View All

    Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

    Completed target enrollment in Phase 1 monotherapy dose expansion study of micvotabart pelidotin (MICVO) in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) in the first quarter of 2026 Updated data from MICVO Phase 1 monotherapy study in 2L+ R/M HNSCC on track for mid-year 2026; to include patients treated with modified weight-based dosing and patients treated with total body weight dosing Updated data from MICVO Phase 1/2 dose escalation study in combination with KEYTRUDA® in 1L/2L+ R/M HNSCC on track for the second half of 2026 Announced appointment of Thomas Civik as Interim Chief Executive Officer Expected cash runway into the fourth quarter of 2026 BOSTO

    3/23/26 7:00:00 AM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity

    BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a leadership transition to continue execution and advancement of the Company's strategic and clinical goals. Thomas Civik, a member of Pyxis Oncology's Board of Directors since the Company's IPO and a highly experienced biotechnology executive with a proven track record in advancing cancer therapeutics, has been appointed Interim Chief Executive Officer, effective immediately. Lara S. Sullivan, M.D., has stepped down from her roles as President, Chief Executive Officer and Chief Medical Officer. With

    2/3/26 6:45:00 AM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ENvue Medical Appoints Industry Veteran Marc Waldman as Vice President, Commercial

    TYLER, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ:FEED) (NASDAQ:NAOV) ("ENvue," "ENvue Medical" or the "Company"), a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings, today announced the appointment of Marc Waldman as Vice President, Commercial. In this role, Mr. Waldman will lead ENvue's U.S. commercialization strategy, with a focus on expanding its existing presence in 38 hospitals and accelerating revenue across the Company's enteral platform. "Marc is a highly accomplished sales leader with extensive GPO and IDN expertise and long-standing relationships th

    1/21/26 8:30:00 AM ET
    $FEED
    $NAOV
    Industrial Specialties
    Health Care

    $ADVM
    $AGTC
    $CLNN
    $KALA
    Financials

    Live finance-specific insights

    View All

    Schrödinger Reports Fourth Quarter and Full-Year 2025 Financial Results

    2025 Total Revenue of $256 Million 2025 Software Revenue of $200 Million; 2025 Software ACV of $198 Million Strong Balance Sheet Supports Path to Positive Adjusted EBITDA by Year-End 2028 Accelerating Transition to Ratable, Hosted Software Revenue Schrödinger, Inc. (NASDAQ:SDGR) today announced financial results for the fourth quarter and full-year ended December 31, 2025, and provided its 2026 outlook and 2028 financial objectives. "Schrödinger's performance in 2025, marked by 23% total revenue growth and 11% software revenue growth, is a testament to the resilience of our business and the unique value we provide," said Ramy Farid, Ph.D., chief executive officer of Schrödinger. "

    2/25/26 4:05:00 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Schrödinger to Announce Fourth Quarter and Full-Year 2025 Financial Results on February 25

    Schrödinger, Inc. (NASDAQ:SDGR) will report its fourth quarter and full-year 2025 financial results on Wednesday, February 25, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed in the "Investors" section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schrödinger's software platform is built on more than 30 years of R&D investment and is licensed b

    2/11/26 8:30:00 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

    46% confirmed objective response rate (ORR) and 92% disease control rate (DCR) observed with MICVO as monotherapy in 2L+ R/M HNSCC at 5.4 mg/kg 71% confirmed ORR and 100% DCR observed with MICVO in combination with KEYTRUDA® (pembrolizumab) in 1L/2L+ R/M HNSCC at 3.6 mg/kg and 4.4 mg/kgUpdated data from ongoing Phase 1 monotherapy study in 2L+ R/M HNSCC expected mid-2026; updated data from ongoing Phase 1/2 study evaluating MICVO in combination with KEYTRUDA®, including in 1L/2L+ R/M HNSCC and other tumor types, expected 2H26 Company to host webcast and conference call today at 8:30 a.m. ET BOSTON, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage comp

    12/18/25 7:00:00 AM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADVM
    $AGTC
    $CLNN
    $KALA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Adverum Biotechnologies Inc.

    SC 13G/A - Adverum Biotechnologies, Inc. (0001501756) (Subject)

    11/14/24 6:57:12 PM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Adverum Biotechnologies Inc.

    SC 13G/A - Adverum Biotechnologies, Inc. (0001501756) (Subject)

    11/14/24 6:40:56 PM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by NanoVibronix Inc.

    SC 13G/A - NanoVibronix, Inc. (0001326706) (Subject)

    11/14/24 5:17:34 PM ET
    $NAOV
    Industrial Specialties
    Health Care